GlassScriptPhysician profile
Stacey L Waring
NPI 1124174198
$4,479.93
in general payments reported to CMS, 2019-2025
34 companies · $568 in 2025
The $568 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $779 · 2020: $311 · 2021: $351 · 2022: $644 · 2023: $916 · 2024: $911 · 2025: $568.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,395.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,395.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,000.97 | 2021-2025 | Ubrelvy, Vraylar, Qulipta |
| Amgen INC. | $689.89 | 2019-2025 | Evenity, Prolia |
| Astrazeneca Pharmaceuticals LP | $556.51 | 2019-2024 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $304.60 | 2020-2025 | Wegovy, Rybelsus, Ozempic |
| Pfizer INC. | $243.65 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $240.36 | 2023-2025 | Gemtesa |
| Biohaven Pharmaceutical Holding Company LTD. | $231.83 | 2022 | |
| Glaxosmithkline, LLC. | $175.05 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Amarin Pharma, INC. | $141.86 | 2019-2021 | |
| Astellas Pharma US INC | $99.66 | 2019-2024 | Veozah, Myrbetriq |
| Novartis Pharmaceuticals Corporation | $98.72 | 2023-2024 | |
| Exact Sciences Corporation | $94.63 | 2023-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $84.14 | 2023-2025 | Mounjaro, Zepbound |
| Merck Sharp & Dohme LLC | $70.25 | 2019-2021 | |
| Averitas Pharma INC. | $39.75 | 2025 | Qutenza |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $37.33 | 2022 | |
| Eisai INC. | $35.72 | 2019 | |
| Idorsia Pharmaceuticals US INC | $31.37 | 2023 | Quviviq |
| Janssen Pharmaceuticals, INC | $30.00 | 2020 | |
| Amneal Pharmaceuticals LLC | $26.67 | 2021-2024 | Unithroid |
| Almatica Pharma LLC | $26.39 | 2024 | Loreev Xr |
| Radius Health, INC. | $26.07 | 2019-2025 | Tymlos |
| Neuronetics, INC. | $22.16 | 2025 | Neurostar Tms Therapy System |
| Phathom Pharmaceuticals, INC. | $20.91 | 2024 | Voquezna |
| Endo Pharmaceuticals INC. | $19.25 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.82 | 2023 | Trintellix |
| Kowa Pharmaceuticals America, INC. | $18.08 | 2022 | |
| Vivus LLC | $16.93 | 2019 | |
| Antares Pharma, INC. | $16.70 | 2025 | Xyosted |
| Medtronic, INC. | $15.75 | 2025 | Minimed 780g |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.87 | 2024 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $14.31 | 2019 | |
| Shire North American Group INC | $11.77 | 2019 | |
| Dynavax Technologies Corporation | $4.96 | 2024 | Heplisav-B |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacey Waring listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.